Justicidin CCAS# 17803-12-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 17803-12-2 | SDF | Download SDF |
PubChem ID | 493173 | Appearance | Powder |
Formula | C22H18O7 | M.Wt | 394.4 |
Type of Compound | Lignans | Storage | Desiccate at -20°C |
Synonyms | Neojusticin B | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 9-(1,3-benzodioxol-5-yl)-4,6,7-trimethoxy-1H-benzo[f][2]benzofuran-3-one | ||
SMILES | COC1=C(C=C2C(=C1)C(=C3COC(=O)C3=C2OC)C4=CC5=C(C=C4)OCO5)OC | ||
Standard InChIKey | RHTTTZYNBXNPSZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H18O7/c1-24-16-7-12-13(8-17(16)25-2)21(26-3)20-14(9-27-22(20)23)19(12)11-4-5-15-18(6-11)29-10-28-15/h4-8H,9-10H2,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Justicidin C Dilution Calculator
Justicidin C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5355 mL | 12.6775 mL | 25.355 mL | 50.7099 mL | 63.3874 mL |
5 mM | 0.5071 mL | 2.5355 mL | 5.071 mL | 10.142 mL | 12.6775 mL |
10 mM | 0.2535 mL | 1.2677 mL | 2.5355 mL | 5.071 mL | 6.3387 mL |
50 mM | 0.0507 mL | 0.2535 mL | 0.5071 mL | 1.0142 mL | 1.2677 mL |
100 mM | 0.0254 mL | 0.1268 mL | 0.2535 mL | 0.5071 mL | 0.6339 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lapathoside A
Catalog No.:BCX0160
CAS No.:373646-49-2
- Kaempferol 3-(2''-galloylglucoside)
Catalog No.:BCX0159
CAS No.:76343-90-3
- Procumbenoside E
Catalog No.:BCX0158
CAS No.:220182-12-7
- Huzhangoside C
Catalog No.:BCX0157
CAS No.:96315-52-5
- Melliferone
Catalog No.:BCX0156
CAS No.:377724-68-0
- Isorinic acid
Catalog No.:BCX0155
CAS No.:145757-60-4
- Justicidin D
Catalog No.:BCX0154
CAS No.:27041-98-1
- Chinensinaphthol methyl ether
Catalog No.:BCX0153
CAS No.:53965-11-0
- Justicidin B
Catalog No.:BCX0152
CAS No.:17951-19-8
- threo-7,9,9'-Trihydroxy-3,3'-dimethoxy-8-O-4'-neolignan 4-O-beta-D-glucopyranoside
Catalog No.:BCX0151
CAS No.:1009838-88-3
- Dehydropipernonaline
Catalog No.:BCX0150
CAS No.:107584-38-3
- Pyrolaside B analogue
Catalog No.:BCX0149
CAS No.:1053610-99-3
- Massonianoside A
Catalog No.:BCX0162
CAS No.:623945-11-9
- Justicidinoside C
Catalog No.:BCX0163
CAS No.:177912-23-1
- Retrofractamide C
Catalog No.:BCX0164
CAS No.:96386-33-3
- Gerardianin D
Catalog No.:BCX0165
CAS No.:2036276-69-2
- Pyrolone B
Catalog No.:BCX0166
CAS No.:1014978-30-3
- 3alpha-Acetyloxy-25-hydroxyolean-12-en-28-oic acid
Catalog No.:BCX0167
CAS No.:469895-08-7
- Justicidin A
Catalog No.:BCX0168
CAS No.:25001-57-4
- threo-Guaiacylglycerol β-dihydroconiferyl ether
Catalog No.:BCX0169
CAS No.:135820-78-9
- Leonuriside A
Catalog No.:BCX0170
CAS No.:121748-12-7
- (+)-3-Hydroxy-p-menth-1-en-6-one
Catalog No.:BCX0171
CAS No.:120850-08-0
- (-)-Byakangelicin
Catalog No.:BCX0172
CAS No.:23517-02-4
- 5,5'-Oxybis(pyrrolidin-2-one)
Catalog No.:BCX0173
CAS No.:73123-79-2
Design, synthesis, and evaluation of cytotoxic activities of arylnaphthalene lignans and aza-analogs.[Pubmed:33586249]
Arch Pharm (Weinheim). 2021 Jun;354(6):e2000479.
A concise and versatile synthetic strategy for the total synthesis of arylnaphthalene lignans and aza-analogs was developed. The main objective was to develop synthetic tactics for the creation of the lactone and lactam unit that would give access to an array of synthetic, natural, and/or bioactive compounds through rather simple chemical manipulation. The flexibility and potentiality of these new processes were further illustrated by the total synthesis of retrojusticidin B (13b), Justicidin C (14b), and methoxy-vitedoamine A (22a). In this study, a series of novel aryl-naphthalene lignans and aza-analogs were synthesized, and the cytotoxic activities of all compounds on cancer cell growth were evaluated. The target compounds were structurally characterized by (1) H NMR (nuclear magnetic resonance), (13) C NMR, infrared, high-resolution mass spectrometry, and X-ray crystallography. The IC(50) values of these compounds on five tumor cell lines (A549, HS683, MCF-7, SK-MEL-28, and B16-F1) were obtained by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay. Five of the compounds exhibited excellent activity compared to 5-fluorouracil and etoposide against the five cell lines tested, with IC(50) values ranging from 1 to 10 muM.
Development of a mesoporous silica based solid-phase extraction and ultra-performance liquid chromatography-MS/MS method for quantifying lignans in Justicia procumbens.[Pubmed:32040861]
Electrophoresis. 2020 Mar;41(5-6):379-385.
Justicia procumbens is a food and medicine homologous variety, popularly used for making vegetable soups. In this study, a novel mesoporous silica was synthesized and used as the sorbent of SPE for the purification of lignans from J. procumbens. A laboratory-made SPE cartridge was packed with 100 mg of mesoporous silica, which was washed with 10% methanol and eluted using 0.8 mL acetonitrile after sample loading. Afterward, the extract was analyzed by ultra-performance liquid chromatography (UPLC) and MS/MS. All the lignans were efficiently separated in 6 min with the noise level in the range of 50-150 cps. 6'-Hydroxy justicidin B, 6'-hydroxy justicidin A, justicidin B, chinensinaphthol methyl ether, Justicidin C, and neojusticdin A were identified to be the dominant molecular species in J. procumbens with contents of 0.065-0.37 mg/g in three tested sample batches from different geographic origins. In conclusion, the proposed mesoporous silica based SPE UPLC-MS/MS method is efficient in linearity (R(2) = 0.9989-0.9996), sensitivity (LOD =0.13 mug/kg and LOQ =0.42 mug/kg), precision (RSD(intra-day) =3.12 and RSD(inter-day) =4.56), and recovery (83.42-96.11%, RSD =2.88%).
Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic analysis of justicidin B and 6'-hydroxy justicidin C in rats.[Pubmed:27874243]
J Sep Sci. 2017 Feb;40(3):604-611.
Arylnaphthalene lignans have attracted considerable interest with the discovery of their antineoplastic activities. Two such compounds are justicidin B and 6'-hydroxy Justicidin C, both of which have been isolated from the herb Justicia procumbens. We sought to develop and validate a sensitive and accurate, ultra high performance liquid chromatography with electrospray ionization tandem mass spectrometry method for the structural determination and pharmacokinetics of justicidin B and 6'-hydroxy Justicidin C. Chromatographic separation was achieved on an Agilent 300SB-C(18) column using water (0.5% formic acid, 10 mM NH(4) COOH) methanol as the mobile phase. The plasma samples obtained after oral administration of the active extract of Justicia procumbens were successfully analyzed with our novel method, thereby demonstrating its sound applicability and reliability. The lower limit of quantification for justicidin B and 6'-hydroxy Justicidin C was 0.50 and 1.00 ng/mL in 50 muL rat plasma, respectively. The elimination half-life and clearance of justicidin B was estimated to be 1.27 +/- 0.61 h and 5.40 +/- 0.22 L/h/kg while that of 6'-hydroxy Justicidin C was 2.07 +/- 0.70 h and 11.84 +/- 1.06 L/h/kg. This newly developed and validated method was successfully applied to the quantification and pharmacokinetic study of justicidin B and 6'-hydroxy Justicidin C in rats.